Toremifene

Toremifene

File:Toremifene.svg
Systematic (IUPAC) name
2-{4-[(1Z)-4-chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
Pharmacokinetic data
Protein binding	more than 99.5%
Biological half-life	5 days
Identifiers
CAS Number	89778-26-7
ATC code	L02BA02 (WHO)
PubChem	CID 3005573
DrugBank	APRD00391
Chemical data
Formula	C26H28ClNO
Molar mass	405.959 g/mol[[]]
(verify)

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

In 2007 GTx Inc. was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy(ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008

An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009.

References

es:Toremifeno